New cream aims to soothe butterfly skin in Late-Stage trial
NCT ID NCT07482813
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 study tests the safety of SD-101 cream (6% allantoin) in 80 people with epidermolysis bullosa, a condition that causes fragile, blistering skin. Participants must have completed a prior study (SD-007). The main goal is to track any side effects over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SD-101 cream (6% allantoin)
- What this could lead to
- If this cream proves safe, it may offer a way to manage skin symptoms in people with epidermolysis bullosa.
- What could go wrong
- This is an open-label extension focused on safety, not effectiveness. It only includes patients who already completed another study, so results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPIDERMOLYSIS BULLOSA (EB) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a birch bark gel soothe blistering skin disease?
- Gene therapy skin graft aims to heal wounds in 'Butterfly Children'
- Gene therapy for 'Butterfly Skin' disease tracked for 15 years in major safety registry
- Anti-Inflammatory drug may ease swallowing in rare skin disease
- Turmeric and blue light may heal blisters in rare skin disease
- New hope for blistering skin diseases: drug targets antibodies to heal wounds